Morphologic and molecular heterogeneity in imatinib-resistant GIST

被引：0
|
作者：
Liegl, B.
Kepten, I.
Donsky, R.
Fletcher, C. D. M.
Corless, C. L.
Fletcher, J. A.
机构：
[1] Brigham & Womens Hosp, Boston, MA 02115 USA
[2] Med Univ Graz, Graz, Austria
[3] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
来源：
LABORATORY INVESTIGATION | 2008年 / 88卷
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
51
引用
收藏
页码：14A / 14A
页数：1
相关论文
共 50 条
  • [21] Management of imatinib-resistant CML patients
    Linke, Rolf
    Dempke, Wolfram
    ONKOLOGIE, 2007, 30 (11): : 574 - 580
  • [22] Dasatinib is effective in imatinib-resistant CML
    Cannell, Emma
    LANCET ONCOLOGY, 2007, 8 (04): : 286 - 286
  • [23] Morphologic features of response to Gleevec (Imatinib) treatment of GIST
    Colecchia, M
    Diment, J
    INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY, 2003, 11 (02) : 119 - 119
  • [24] A phase I study of nilotinib alone and in combination with imatinib in patients (PTS) with imatinib-resistant gastrointestinal stromal tumors (GIST) -: Study update
    Reichardt, Peter
    Casali, Paolo G.
    Blay, Jean-Yves
    von Mehren, Margaret
    Schoffski, Patrick
    Tanaka, Chiaki
    Jalaluddin, Muhammad
    Veronese, Maria Luisa
    Demetri, George D.
    ANNALS OF ONCOLOGY, 2006, 17 : 138 - 138
  • [25] A phase I study of AMN107 alone and in combination with imatinib in patients (pts) with imatinib-resistant gastrointestinal stromal tumors (GIST).
    Reichardt, P.
    Casali, P. G.
    Blay, J.
    Von Mehren, M.
    Schoffski, P.
    Hosseinzadeh, S.
    Tanaka, C.
    Gsponer, T.
    Veronese, M. L.
    Demetri, G. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 531S - 531S
  • [26] The role of novel fusion genes in human GIST cell lines derived from imatinib-resistant GIST patients: A therapeutic potential of fusion gene
    Cho, Woo-Cheol
    Shin, Young-Kyoung
    Na, Young-Soon
    Ryu, Min-Hee
    Ku, Ja-Lok
    Kang, Yoon-Koo
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2020, 529 (03) : 699 - 706
  • [27] Molecular analysis of secondary kinase mutations in imatinib-resistant gastrointestinal stromal tumors
    Ken-Hong Lim
    Ming-Jer Huang
    Li-Tzong Chen
    Tsang-En Wang
    Chien-Liang Liu
    Cheng-Shyong Chang
    Mei-Chin Liu
    Reuy-Kuen Hsieh
    Chin-Yuan Tzen
    Medical Oncology, 2008, 25 : 207 - 213
  • [28] Development of imatinib-resistant clones in metastatic GISTs
    Nature Clinical Practice Oncology, 2008, 5 (1): : 8 - 8
  • [29] Molecular analysis of secondary kinase mutations in imatinib-resistant gastrointestinal stromal tumors
    Lim, Ken-Hong
    Huang, Ming-Jer
    Chen, Li-Tzong
    Wang, Tsang-En
    Liu, Chien-Liang
    Chang, Cheng-Shyong
    Liu, Mei-Chin
    Hsieh, Reuy-Kuen
    Tzen, Chin-Yuan
    MEDICAL ONCOLOGY, 2008, 25 (02) : 207 - 213
  • [30] A phase I study of nilotinib alone and in combination with imatinib (IM) in patients (pts) with imatinib-resistant gastrointestinal stromal tumors (GIST) - Study update
    Von Mehren, M.
    Reichardt, P.
    Casali, P. G.
    Blay, J.
    Debiec-Rychter, M.
    Dumez, H.
    Cheung, W.
    Feifel, B.
    Veronese, M.
    Demetri, G. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345